MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:42Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:H1 receptor antagonists]]
			[[Category:Mast cell stabilizers]]
			[[Category:Ophthalmic antihistamines]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #269

2026-05-23T04:15:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #269

New page

{{MedTemplate
| generic = Olopatadine
| brand = Patanol, Pataday (ophthalmic, now OTC), Patanase (intranasal)
| structure =
| classes = [[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]], [[:Category:Mast_cell_stabilizers|Mast cell stabilizer]], [[:Category:Ophthalmic_antihistamines|Ophthalmic antihistamine]]
| uses = <vote slug="allergic-conjunctivitis-use">Allergic conjunctivitis (ophthalmic)</vote>, <vote slug="allergic-rhinitis-use">Allergic rhinitis (intranasal Patanase)</vote>
| starting_dose = Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID
| preparations = 0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray
| fda_max = Once daily (Pataday 0.7%); BID (other ophthalmic)
| pill_id =
| routes = Topical ophthalmic, intranasal
| onset = Symptom relief within 30-60 minutes
| duration = 24 hours (0.7% formulation); 8-12 hours (lower-strength)
| halflife = ~3 hours (systemic, when measurable; topical action dominates)<ref name="pataday-label">FDA Prescribing Information, Pataday (olopatadine HCl) ophthalmic solution, Alcon/Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206276s003lbl.pdf</ref>
| bioavailability = Topical with minimal systemic absorption<ref name="pataday-label" />
| pregnancy = Generally considered safe; minimal systemic exposure.{{citation needed}}
| legal = OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US
| mechanism = <vote slug="olopatadine-mech-claim">Olopatadine is a dual-acting agent: selective H1 receptor antagonism provides immediate symptom relief from existing mediator release, while mast cell membrane stabilization prevents further degranulation; the combination produces both fast and sustained ocular antiallergic effect.</vote> Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients<ref name="pataday-label" />.
}}

== References ==
<references />

Olopatadine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #269